Group 1 - The company plans to distribute a cash dividend of 6 yuan per 10 shares, totaling approximately 357 million yuan, based on a total of 595,000,033 shares [3][35][40] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [36][41] - The company reported a net profit of approximately 20.8 million yuan for the first half of 2025, with available profits for distribution amounting to approximately 2.19 billion yuan [38][40] Group 2 - The company has appointed Chen Zhenbo as the new sponsor representative for ongoing supervision, replacing the previous representative due to internal job changes [8][9] - The company will hold its second extraordinary general meeting of 2025 on September 22, 2025, with both on-site and online voting options available for shareholders [11][12][13] Group 3 - The company has effectively managed its fundraising, with approximately 1.31 billion yuan utilized from the total raised amount of approximately 2.28 billion yuan [48][49] - The remaining balance of unused funds is approximately 1.05 billion yuan, with a portion invested in financial products [49][50] - The company has established a special account for managing the raised funds, ensuring compliance with regulatory requirements [50][51]

中国经济网北京8月5日讯华兰疫苗（301207）(301207.SZ)今日收报18.87元，跌幅1.15%。 华兰疫苗于2022年2月18日在深交所创业板上市，公开发行的股票数量为4001.00万股，发行价格为56.88 元/股，保荐机构(主承销商)为华泰联合证券有限责任公司，保荐代表人为贾鹏、刘晓宁。 华兰疫苗首次公开发行股票的发行费用总额为3156.57万元，其中，华泰联合证券有限责任公司获得承 销费用、保荐费用合计2200.00万元。 2023年5月30日，华兰疫苗发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以公 司现有总股本400,010,000股为基数，向全体股东每10股派3.00元人民币现金，同时，以资本公积金向全 体股东每10股转增5股。本次权益分派股权登记日为2023年6月6日，除权除息日为2023年6月7日。 华兰疫苗首次公开发行股票募集资金总额为22.76亿元，扣除含税发行费用3156.57万元，实际募集资金 净额为22.44亿元。华兰疫苗此次募集资金比原计划少2.51亿元，公司2021年11月12日披露招股书注册稿 显示，公司拟募集资金24.95亿元，分别用于流 ...